New and Old TSPO PET Radioligands for Imaging Brain Microglial Activation in Neurodegenerative Disease

Overview

Journal Curr Neurol Neurosci Rep

Specialty Neurology

Date 2019 Apr 4

PMID 30941587

Citations 38

Authors

Laura Best

Christine Ghadery

Nicola Pavese

Yen Foung Tai

Antonio P Strafella

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: We will discuss the developments in TSPO PET imaging and the contribution this technique has had to understanding neuroinflammation in vivo, as well as the limitations inherent to the currently available radioligands and the potential future direction.

Recent Findings: Positron emission tomography (PET) imaging targeting the translocator protein 18 kDa (TSPO) has led to major advances in understanding the pathological role played by microglia activation and neuroinflammation in a diverse range of neurodegenerative conditions. The first-generation radioligand [C](R)-PK11195 has been the most widely studied and has led to considerable advancements in defining the role of neuroinflammation in neuronal degeneration and dysfunction. However, limitations including low signal-to-noise ratio and high nonspecific binding have led to the development of new TSPO-specific radioligands in an attempt to improve the quality of TSPO imaging. Unfortunately, these new radioligands have not been without their own problems, and the expected improvement in image quality has not been achieved.

Citing Articles

Current advances in the structure-activity relationship (SAR) analysis of the old/new 18-kDa translocator protein ligands.

Singh P, Singh V, Gond C, Singh D, Tiwari A Mol Divers. 2024; .

PMID: 39630364 DOI: 10.1007/s11030-024-10963-0.

Parkinson's Disease: Biomarkers for Diagnosis and Disease Progression.

Arya R, Haque A, Shakya H, Billah M, Parvin A, Rahman M Int J Mol Sci. 2024; 25(22).

PMID: 39596444 PMC: 11594627. DOI: 10.3390/ijms252212379.

Tetramerization of PKM2 Alleviates Traumatic Brain Injury by Ameliorating Mitochondrial Damage in Microglia.

Zhu H, Zhang H, Zhao X, Zhang L, Liu X, Zhang Z J Neuroimmune Pharmacol. 2024; 19(1):48.

PMID: 39196455 DOI: 10.1007/s11481-024-10138-6.

Imaging Biomarkers in Prodromal and Earliest Phases of Parkinson's Disease.

Theis H, Pavese N, Rektorova I, van Eimeren T J Parkinsons Dis. 2024; 14(s2):S353-S365.

PMID: 38339941 PMC: 11492013. DOI: 10.3233/JPD-230385.

TSPO is a potential independent prognostic factor associated with cellular respiration and p16 in head and neck squamous cell carcinoma.

Tuominen S, Nissi L, Kukkula A, Routila J, Huusko T, Leivo I Front Oncol. 2024; 13:1298333.

PMID: 38162485 PMC: 10755888. DOI: 10.3389/fonc.2023.1298333.

References

Yasuno F, Kosaka J, Ota M, Higuchi M, Ito H, Fujimura Y . Increased binding of peripheral benzodiazepine receptor in mild cognitive impairment-dementia converters measured by positron emission tomography with [¹¹C]DAA1106. Psychiatry Res. 2012; 203(1):67-74. DOI: 10.1016/j.pscychresns.2011.08.013. View

Dupont A, Largeau B, Santiago Ribeiro M, Guilloteau D, Tronel C, Arlicot N . Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases. Int J Mol Sci. 2017; 18(4). PMC: 5412369. DOI: 10.3390/ijms18040785. View

Gerhard A, Banati R, Goerres G, Cagnin A, Myers R, Gunn R . [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology. 2003; 61(5):686-9. DOI: 10.1212/01.wnl.0000078192.95645.e6. View

Fan Z, Aman Y, Ahmed I, Chetelat G, Landeau B, Chaudhuri K . Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia. Alzheimers Dement. 2014; 11(6):608-21.e7. DOI: 10.1016/j.jalz.2014.06.016. View

Cagnin A, Rossor M, Sampson E, Mackinnon T, Banati R . In vivo detection of microglial activation in frontotemporal dementia. Ann Neurol. 2004; 56(6):894-7. DOI: 10.1002/ana.20332. View

Gulyas B, Vas A, Toth M, Takano A, Varrone A, Cselenyi Z . Age and disease related changes in the translocator protein (TSPO) system in the human brain: positron emission tomography measurements with [11C]vinpocetine. Neuroimage. 2011; 56(3):1111-21. DOI: 10.1016/j.neuroimage.2011.02.020. View

Varrone A, Mattsson P, Forsberg A, Takano A, Nag S, Gulyas B . In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in Alzheimer's disease patients. Eur J Nucl Med Mol Imaging. 2013; 40(6):921-31. DOI: 10.1007/s00259-013-2359-1. View

Corcia P, Tauber C, Vercoullie J, Arlicot N, Prunier C, Praline J . Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One. 2013; 7(12):e52941. PMC: 3534121. DOI: 10.1371/journal.pone.0052941. View

Edison P, Archer H, Gerhard A, Hinz R, Pavese N, Turkheimer F . Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis. 2008; 32(3):412-9. DOI: 10.1016/j.nbd.2008.08.001. View

10.

Bartels A, Willemsen A, Doorduin J, de Vries E, Dierckx R, Leenders K . [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?. Parkinsonism Relat Disord. 2009; 16(1):57-9. DOI: 10.1016/j.parkreldis.2009.05.005. View

11.

Hamelin L, Lagarde J, Dorothee G, Leroy C, Labit M, Comley R . Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging. Brain. 2016; 139(Pt 4):1252-64. DOI: 10.1093/brain/aww017. View

12.

Guo Q, Owen D, Rabiner E, Turkheimer F, Gunn R . Identifying improved TSPO PET imaging probes through biomathematics: the impact of multiple TSPO binding sites in vivo. Neuroimage. 2012; 60(2):902-10. PMC: 3314937. DOI: 10.1016/j.neuroimage.2011.12.078. View

13.

Morton A, Wood N, Hastings M, Hurelbrink C, Barker R, Maywood E . Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J Neurosci. 2005; 25(1):157-63. PMC: 6725210. DOI: 10.1523/JNEUROSCI.3842-04.2005. View

14.

Wilson A, Garcia A, Parkes J, McCormick P, Stephenson K, Houle S . Radiosynthesis and initial evaluation of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors. Nucl Med Biol. 2008; 35(3):305-14. DOI: 10.1016/j.nucmedbio.2007.12.009. View

15.

Rizzo G, Veronese M, Tonietto M, Zanotti-Fregonara P, Turkheimer F, Bertoldo A . Kinetic modeling without accounting for the vascular component impairs the quantification of [(11)C]PBR28 brain PET data. J Cereb Blood Flow Metab. 2014; 34(6):1060-9. PMC: 4050251. DOI: 10.1038/jcbfm.2014.55. View

16.

Okello A, Edison P, Archer H, Turkheimer F, Kennedy J, Bullock R . Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology. 2009; 72(1):56-62. PMC: 2817573. DOI: 10.1212/01.wnl.0000338622.27876.0d. View

17.

Turkheimer F, Rizzo G, Bloomfield P, Howes O, Zanotti-Fregonara P, Bertoldo A . The methodology of TSPO imaging with positron emission tomography. Biochem Soc Trans. 2015; 43(4):586-92. PMC: 4613512. DOI: 10.1042/BST20150058. View

18.

Boutin H, Chauveau F, Thominiaux C, Gregoire M, James M, Trebossen R . 11C-DPA-713: a novel peripheral benzodiazepine receptor PET ligand for in vivo imaging of neuroinflammation. J Nucl Med. 2007; 48(4):573-81. DOI: 10.2967/jnumed.106.036764. View

19.

Ohnishi A, Senda M, Yamane T, Sasaki M, Mikami T, Nishio T . Human whole-body biodistribution and dosimetry of a new PET tracer, [(11)C]ketoprofen methyl ester, for imagings of neuroinflammation. Nucl Med Biol. 2014; 41(7):594-9. DOI: 10.1016/j.nucmedbio.2014.04.008. View

20.

Serrano-Pozo A, Frosch M, Masliah E, Hyman B . Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2012; 1(1):a006189. PMC: 3234452. DOI: 10.1101/cshperspect.a006189. View